(Q40099519)

17 September 2017

title

Activation of adenosine monophosphate activated protein kinase inhibits growth of multiple myeloma cells (English)

1 reference

17 September 2017

1 reference

Philipp Baumann

1

1 reference

17 September 2017

Sonja Mandl-Weber

2

1 reference

17 September 2017

Bertold Emmerich

3

1 reference

17 September 2017

Christian Straka

4

1 reference

17 September 2017

Ralf Schmidmaier

5

1 reference

17 September 2017

language of work or name

English

0 references

publication date

4 July 2007

1 reference

Experimental Cell Research

17 September 2017

published in

1 reference

17 September 2017

volume

313

1 reference

17 September 2017

issue

16

1 reference

17 September 2017

page(s)

3592-3603

1 reference

Tipifarnib and bortezomib are synergistic and overcome cell adhesion-mediated drug resistance in multiple myeloma and acute myeloid leukemia

17 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2007.06.020

The HMG-CoA reductase inhibitor simvastatin overcomes cell adhesion-mediated drug resistance in multiple myeloma by geranylgeranylation of Rho protein and activation of Rho kinase

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2007.06.020

IGF-1 receptor tyrosine kinase inhibition by the cyclolignan PPP induces G2/M-phase accumulation and apoptosis in multiple myeloma cells.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2007.06.020

Insulinlike growth factor-I signaling in multiple myeloma: downstream elements, functional correlates, and pathway cross-talk

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2007.06.020

Targeting receptor kinases by a novel indolinone derivative in multiple myeloma: abrogation of stroma-derived interleukin-6 secretion and induction of apoptosis in cytogenetically defined subgroups

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2007.06.020

Map kinase signaling pathways and hematologic malignancies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2007.06.020

AMPK, the metabolic syndrome and cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2007.06.020

The AMP-activated protein kinase cascade--a unifying system for energy control

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2007.06.020

The AMP-activated/SNF1 protein kinase subfamily: metabolic sensors of the eukaryotic cell?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2007.06.020

5-Aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside inhibits cancer cell proliferation in vitro and in vivo via AMP-activated protein kinase

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2007.06.020

Cell cycle regulation via p53 phosphorylation by a 5'-AMP activated protein kinase activator, 5-aminoimidazole- 4-carboxamide-1-beta-D-ribofuranoside, in a human hepatocellular carcinoma cell line

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2007.06.020

Acadesine activates AMPK and induces apoptosis in B-cell chronic lymphocytic leukemia cells but not in T lymphocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2007.06.020

Treosulfan-induced apoptosis in acute myeloid leukemia cells is accompanied by translocation of protein kinase C delta and enhanced by bryostatin-1.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2007.06.020

Identification of molecular target of AMP-activated protein kinase activator by affinity purification and mass spectrometry

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2007.06.020

The 5'-AMP-activated protein kinase inhibits the transcriptional stimulation by glucose in liver cells, acting through the glucose response complex

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2007.06.020

Inhibition of protein geranylgeranylation induces apoptosis in myeloma plasma cells by reducing Mcl-1 protein levels

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2007.06.020

Downstream effectors of oncogenic ras in multiple myeloma cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2007.06.020

Specific roles for the PI3K and the MEK-ERK pathway in IGF-1-stimulated chemotaxis, VEGF secretion and proliferation of multiple myeloma cells: study in the 5T33MM model.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2007.06.020

Cell responses to FGFR3 signalling: growth, differentiation and apoptosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2007.06.020

Functional interleukin-7 receptors (IL-7Rs) are expressed by marrow stromal cells: binding of IL-7 increases levels of IL-6 mRNA and secreted protein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2007.06.020

Inhibition of the insulin-like growth factor receptor-1 tyrosine kinase activity as a therapeutic strategy for multiple myeloma, other hematologic malignancies, and solid tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2007.06.020

Ligands of peroxisome proliferator-activated receptor gamma induce apoptosis in multiple myeloma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2007.06.020

Human multiple myeloma cells express peroxisome proliferator-activated receptor gamma and undergo apoptosis upon exposure to PPARgamma ligands

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2007.06.020

Thiazolidinediones can rapidly activate AMP-activated protein kinase in mammalian tissues

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2007.06.020

AMP-activated protein kinase activators can inhibit the growth of prostate cancer cells by multiple mechanisms

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2007.06.020

N- and K-ras oncogenes in plasma cell dyscrasias.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2007.06.020

Insulin-like growth factor induces the survival and proliferation of myeloma cells through an interleukin-6-independent transduction pathway

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2007.06.020

Effects of stimulation of AMP-activated protein kinase on insulin-like growth factor 1- and epidermal growth factor-dependent extracellular signal-regulated kinase pathway

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2007.06.020

A possible linkage between AMP-activated protein kinase (AMPK) and mammalian target of rapamycin (mTOR) signalling pathway

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2007.06.020

Transcriptional inactivation of STAT3 by PPARgamma suppresses IL-6-responsive multiple myeloma cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2007.06.020

PPARgamma-independent induction of growth arrest and apoptosis in prostate and bladder carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2007.06.020

C75, a fatty acid synthase inhibitor, reduces food intake via hypothalamic AMP-activated protein kinase

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2007.06.020

Inhibition of adenosine monophosphate-activated protein kinase induces apoptosis in multiple myeloma cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2007.06.020

10.1016/J.YEXCR.2007.06.020

7 January 2021

Identifiers

DOI

1 reference

17 September 2017

1 reference